Medical devices, healthcare technology and the business of care
PMA approval · P230013

Edwards EVOQUE Tricuspid Valve Replacement System

Edwards Lifesciences, LLC · Decision date Feb 1, 2024

MEDTECHLEDGER EXPLANATIONP230013

What did the FDA approve?

The FDA approved the Edwards EVOQUE Tricuspid Valve Replacement System on February 1, 2024, under PMA number P230013. The applicant is Edwards Lifesciences, LLC, and the device is classified under product code NPW as a percutaneously delivered prosthesis and tricuspid valve in the cardiovascular specialty.

The approval statement describes the device as indicated for improving health status in patients with symptomatic severe tricuspid regurgitation despite optimal medical therapy, when a heart team deems tricuspid valve replacement appropriate. This is a reported intended use, not independent proof of safety or clinical effectiveness. The record does not include supplement type, supplement reason, or additional clinical data.

FDA approval order statement

Approval for the Edwards EVOQUE Tricuspid Valve Replacement System. The device is indicated for the improvement of health status in patients with symptomatic severe tricuspid regurgitation (TR) despite optimal medical therapy (OMT), in whom tricuspid valve replacement is deemed appropriate by a heart team.
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Feb 1, 2024

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P230013
Regulatory pathway
Premarket approval application
Product code
NPW
Decision code
APPR
Decision date
Feb 1, 2024
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Percutaneously Delivered Prostheses and Tricuspid Valves.

Product code
NPW
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P230013 received

    Application receipt date recorded by FDA.

  2. P230013 · FDA decision

    APPR

  3. P230013/S027 · Related supplement

    EVOQUE Tricuspid Valve Replacement System

  4. P230013/S029 · Related supplement

    Edwards EVOQUE Tricuspid Valve Replacement System

  5. P230013/S033 · Related supplement

    EVOQUE Tricuspid Valve Replacement System

  6. P230013/S034 · Related supplement

    Edwards EVOQUE Tricuspid Valve Replacement System (9850EV)

Timeline entries are records held by MedtechLedger for P230013. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230013

Product / regulatory recordCompanyPathwayDecision dateSource
Edwards Lifesciences, LLCPMA supplementSep 16, 2026FDA
Edwards Lifesciences, LLCPMA supplementOct 19, 2026FDA
Edwards Lifesciences, LLCPMA supplementOct 21, 2026FDA
Edwards Lifesciences, LLCPMA supplementOct 28, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Edwards Lifesciences, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
One Edwards Way, Irvine, CA, 92614

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records